help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on December 14, 2004
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2004-0952
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/3/1294    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Odvina, C. V.
Right arrow Articles by Pak, C. Y.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Odvina, C. V.
Right arrow Articles by Pak, C. Y.C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Osteoporosis

Submitted on May 19, 2004
Accepted on December 1, 2004

SEVERELY SUPPRESSED BONE TURNOVER: A POTENTIAL COMPLICATION OF ALENDRONATE THERAPY

Clarita V. Odvina M.D.*, Joseph E. Zerwekh Ph.D., D. Sudhaker Rao M.B, B.S., Naim Maalouf M.D., Frank A. Gottschalk M.D., and Charles Y.C. Pak M.D.

Clarita V. Odvina Center for Mineral Metabolism and Clinical Research and Division of Orthopedic Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8885; and Division of Bone and Mineral Metabolism, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202

* To whom correspondence should be addressed. E-mail: clarita.odvina{at}utsouthwestern.edu.

Alendronate, an inhibitor of bone resorption, is widely used in osteoporosis treatment. However, concerns have been raised about potential oversuppression of bone turnover during long-term use. We report on 9 patients who sustained spontaneous non-spinal fractures while on alendronate therapy, six of whom displayed either delayed or absent fracture healing for 3 months-2 yr during therapy.

Histomorphometric analysis of the cancellous bone showed markedly suppressed bone formation, with reduced or absent osteoblastic surface in most patients. Osteoclastic surface was low or low normal in 8 patients and eroded surface was decreased in 4. Matrix synthesis was markedly diminished with absence of double-tetracycline label and absent or reduced single-tetracycline label in all patients. The same trend was seen in the intracortical and endocortical surfaces.

Our findings raise the possibility that severe suppression of bone turnover may develop during long-term alendronate therapy, resulting in increased susceptibility to, and delayed healing of non-spinal fractures. Although co-adminstration of estrogen or glucocorticoids appears to be predisposing factors, this apparent complication can also occur with monotherapy. Our observations emphasize the need for increased awareness and monitoring for the potential development of excessive suppression of bone turnover during long-term alendronate therapy.




This article has been cited by other articles:


Home page
 JBJSHome page
C. M. Capeci and N. C. Tejwani
Bilateral Low-Energy Simultaneous or Sequential Femoral Fractures in Patients on Long-Term Alendronate Therapy
J. Bone Joint Surg. Am., November 1, 2009; 91(11): 2556 - 2561.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Musculoskeletal DiseasesHome page
E. M. Lewiecki
Denosumab in postmenopausal osteoporosis: what the clinician needs to know
Therapeutic Advances in Musculoskeletal Diseases, October 1, 2009; 1(1): 13 - 26.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Pozzi, S. Vallet, S. Mukherjee, D. Cirstea, N. Vaghela, L. Santo, E. Rosen, H. Ikeda, Y. Okawa, T. Kiziltepe, et al.
High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties
Clin. Cancer Res., September 15, 2009; 15(18): 5829 - 5839.
[Abstract] [Full Text] [PDF]

Home page
 Age AgeingHome page
T. Ali and R. H. Jay
Spontaneous femoral shaft fracture after long-term alendronate
Age Ageing, September 1, 2009; 38(5): 625 - 626.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
K. A. Kennel and M. T. Drake
Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management
Mayo Clin. Proc., July 1, 2009; 84(7): 632 - 638.
[Abstract] [Full Text] [PDF]

Home page
 BMJ Case ReportsHome page
F. Leung, T.-W. Lau, M. To, K. D.-K. Luk, and A. W. C. Kung
Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates
BMJ Case Reports, March 5, 2009; 2009(mar05_1): bcr1020081073 - bcr1020081073.
[Abstract] [Full Text]

Home page
 IBMS BoneKEyHome page
N. A. Andrews
Postoperative Management of Hip Fractures: Recent inaugural IBMS BoneKEy Online Forum focused on pharmacological and non-pharmacological approaches to managing patients post-hip fracture
IBMS BoneKEy, February 1, 2009; 6(2): 55 - 62.
[Full Text] [PDF]

Home page
 NEJMHome page
R. S. Weinstein, P. K. Roberson, and S. C. Manolagas
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
N. Engl. J. Med., January 1, 2009; 360(1): 53 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. T. Drake, B. L. Clarke, and S. Khosla
Bisphosphonates: Mechanism of Action and Role in Clinical Practice
Mayo Clin. Proc., September 1, 2008; 83(9): 1032 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Visekruna, D. Wilson, and F. E. McKiernan
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2948 - 2952.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. B.K. Kwek, J. S.B. Koh, T. S. Howe, P. Lee, M. J. Seibel, B. A. Lenart, D. G. Lorich, and J. M. Lane
More on Atypical Fractures of the Femoral Diaphysis
N. Engl. J. Med., July 17, 2008; 359(3): 316 - 318.
[Full Text] [PDF]

Home page
 JBJSHome page
L. Gehrig, J. Lane, and M. I. O'Connor
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374.
[Full Text] [PDF]

Home page
 The OncologistHome page
A. Brufsky, N. Bundred, R. Coleman, R. Lambert-Falls, R. Mena, P. Hadji, L. Jin, N. Schenk, S. Ericson, E. A. Perez, et al.
Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole
Oncologist, May 1, 2008; 13(5): 503 - 514.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
Should We Be Concerned About Jaw Osteonecrosis with Oral Bisphosphonates?
Journal Watch (General), April 8, 2008; 2008(408): 1 - 1.
[Full Text]

Home page
 NEJMHome page
B. A. Lenart, D. G. Lorich, and J. M. Lane
Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate
N. Engl. J. Med., March 20, 2008; 358(12): 1304 - 1306.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
E. J. MacLaughlin and C. L. Raehl
ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
Am. J. Health Syst. Pharm., February 15, 2008; 65(4): 343 - 357.
[Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
I. R. Reid
Pathogenesis of Osteonecrosis of the Jaw
IBMS BoneKEy, February 1, 2008; 5(2): 69 - 77.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
S.L. Ruggiero and S.J. Drew
Osteonecrosis of the Jaws and Bisphosphonate Therapy
Journal of Dental Research, November 1, 2007; 86(11): 1013 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
M. M. McDonald, A. Schindeler, and D. G. Little
Bisphosphonate Treatment and Fracture Repair
IBMS BoneKEy, September 1, 2007; 4(9): 236 - 251.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Fujii, T. Hamano, S. Mikami, Y. Nagasawa, Y. Isaka, T. Moriyama, M. Horio, E. Imai, M. Hori, and T. Ito
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD)
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1601 - 1607.
[Abstract] [Full Text] [PDF]

Home page
 J Bone Joint Surg BrHome page
D. G. Little, M. Ramachandran, and A. Schindeler
The anabolic and catabolic responses in bone repair
J Bone Joint Surg Br, April 1, 2007; 89-B(4): 425 - 433.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. J. Bolland, A. B. Grey, A. M. Horne, S. E. Briggs, M. G. Thomas, R. B. Ellis-Pegler, A. F. Woodhouse, G. D. Gamble, and I. R. Reid
Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1283 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Shoback
Update in Osteoporosis and Metabolic Bone Disorders
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 747 - 753.
[Abstract] [Full Text] [PDF]

Home page
 J Bone Joint Surg BrHome page
S.-K. Goh, K. Y. Yang, J. S. B. Koh, M. K. Wong, S. Y. Chua, D. T. C. Chua, and T. S. Howe
Subtrochanteric insufficiency fractures in patients on alendronate therapy: A CAUTION
J Bone Joint Surg Br, March 1, 2007; 89-B(3): 349 - 353.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. G. G. Russell
Bisphosphonates: Mode of Action and Pharmacology
Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
M. R. McClung
Bisphosphonate Therapy: To Stop or Not to Stop?
IBMS BoneKEy, February 1, 2007; 4(2): 78 - 82.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. L. Teitelbaum
Osteoclasts: What Do They Do and How Do They Do It?
Am. J. Pathol., February 1, 2007; 170(2): 427 - 435.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
N. B. Watts, S. T. Harris, M. R. McClung, J. P. Bilezikian, S. L. Greenspan, and M. M. Luckey
Bisphosphonates and osteonecrosis of the jaw.
Ann Intern Med, November 21, 2006; 145(10): 791 - 792.
[Full Text] [PDF]

Home page
 NEJMHome page
R. Armamento-Villareal, N. Napoli, V. Panwar, and D. Novack
Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis
N. Engl. J. Med., November 9, 2006; 355(19): 2048 - 2050.
[Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
American Dental Association Council on Scientific
Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations.
J Am Dent Assoc, August 1, 2006; 137(8): 1144 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. Seeman and P. D. Delmas
Bone quality--the material and structural basis of bone strength and fragility.
N. Engl. J. Med., May 25, 2006; 354(21): 2250 - 2261.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S.-B. Woo, J. W. Hellstein, and J. R. Kalmar
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Ann Intern Med, May 16, 2006; 144(10): 753 - 761.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
T. J. Martin
Current, New and Emerging Anti-Resorptive Drugs; Antibody Blockade Of RANKL Action
IBMS BoneKEy, May 1, 2006; 3(5): 42 - 46.
[Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
A. J. Lasser
MORE ABOUT BON
J Am Dent Assoc, April 1, 2006; 137(4): 441 - 441.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Michalska, J. J. Stepan, B. R. Basson, and I. Pavo
The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 870 - 877.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
C. A. MIGLIORATI, J. CASIGLIA, J. EPSTEIN, P. L. JACOBSEN, M. A. SIEGEL, and S.-B. WOO
Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper
J Am Dent Assoc, December 1, 2005; 136(12): 1658 - 1668.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. J. Valimaki and R. Tahtela
Serum Tartrate-Resistant Acid Phosphatase 5b or Amino-Terminal Propeptide of Type I Procollagen for Monitoring Bisphosphonate Therapy in Postmenopausal Osteoporosis?
Clin. Chem., December 1, 2005; 51(12): 2382 - 2385.
[Full Text] [PDF]

Home page
 NEJMHome page
L.J. Deftos
Treatment of Paget's Disease -- Taming the Wild Osteoclast
N. Engl. J. Med., September 1, 2005; 353(9): 872 - 875.
[Full Text] [PDF]

Home page
 NEJMHome page
B. G.M. Durie, M. Katz, J. Crowley, S.-B. Woo, K. Hande, P. G. Richardson, M. Maerevoet, C. Martin, L. Duck, P. Tarassoff, et al.
Osteonecrosis of the Jaw and Bisphosphonates
N. Engl. J. Med., July 7, 2005; 353(1): 99 - 102.
[Full Text] [PDF]

Home page
 BMJHome page
Minerva
BMJ, June 11, 2005; 330(7504): E361 - E361.
[Full Text] [PDF]

Home page
 JWatch GeneralHome page
Is Long-Term Bisphosphonate Therapy Safe?
Journal Watch (General), April 5, 2005; 2005(405): 1 - 1.
[Full Text]

Home page
 BMJHome page
Minerva
BMJ, April 2, 2005; 330(7494): 798 - 798.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. L. Teitelbaum
Osteoporosis and Integrins
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2466 - 2468.
[Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
E. Seeman and G. J. Strewler
Clinical and Basic Research Papers - February 2005 Selections
IBMS BoneKEy, March 1, 2005; 2(3): 1 - 5.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. M. Ott
Long-Term Safety of Bisphosphonates
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1897 - 1899.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society